Abstract
The anticholinergic propiverine (1-methyl-4-piperidyl diphenylpropoxyacetate), which is used for the treatment of overactive bladder syndrome, has functionally active metabolites [M-1 (1-methyl-4-piperidyl diphenylpropoxyacetate N-oxide) and M-2 (1-methyl-4-piperidyl benzilate N-oxide)], but the site of actions of these metabolites is uncertain. Propiverine is rapidly absorbed after oral administration and is extensively biotransformed in the liver, giving rise to several active metabolites (M-1 and M-2). This study determines the effect of M-1 and M-2 on voltage-dependent nifedipine-sensitive inward Ca2+ currents (ICa) using patch-clamp techniques and fluorescent Ca2+ imaging [after electrical field stimulation (EFS) and acetylcholine (ACh)] in the murine urinary bladder. In conventional whole-cell recording, propiverine and M-1 but not M-2 inhibited the peak amplitude of ICa in a concentration-dependent manner at a holding potential of –60 mV (propiverine, Ki = 10 μM; M-1, Ki = 118 μM). M-1 shifted the steady-state inactivation curve of ICa to the left at –90 mV by 7 mV. Carbachol (CCh) reversibly inhibited ICa. This inhibition probably occurred through muscarinic type 3 receptors, coupling with G-proteins, because nanomolar concentrations of 4-diphenylacetoxy-N-methyl-piperidine greatly reduced this inhibition, whereas pirenzepine or 11-([2-[(diethylamino)methyl]-1-piperdinyl]acetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one (AF-DX 116) at concentrations up to 1 μM was almost ineffective. In the presence of M-2, the CCh-induced inhibition of ICa was blocked. In fluorescent Ca2+ imaging, M-2 inhibited EFS-induced and ACh-induced Ca2+ transients. These results suggest that M-1 acts, at least in part, as a Ca2+ channel antagonist (as it inhibited ICa), whereas M-2 has more direct antimuscarinic actions.
Footnotes
-
This work was supported by Grant-in-aid from the Japan Science and Technology Agency 1139-2007 (to N.T.) and Grant-in-aid for Exploratory Research from the Japanese Society for the Promotion of Science 19650733 (to N.T.). This study was also supported by a grant from the Japanese Society for Scientist Exchange Program between the Japan Society for the Promotion of Science and The Royal Society (2006-1-36-RS; to N.T.). H.-L.Z. was awarded a Grant-in-aid from the Japan Society for the Promotion of Science FY2007 (JSPS Postdoctoral Fellowship for Foreign Researcher, P 07196; to N.T.). K.L.B. is a Wellcome Trust Career Development Research Fellow.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.130021.
-
ABBREVIATIONS: ACh, acetylcholine; M-1, 1-methyl-4-piperidyl diphenylpropoxyacetate N-oxide; M-2, 1-methyl-4-piperidyl benzilate N-oxide; ICa, voltage-dependent nifedipine-sensitive inward Ca2+ current; CCh, carbachol; AF-DX 116, 11-([2-[(diethylamino)methyl]-1-piperdinyl]acetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one; 4-DAMP, 4-diphenylacetoxy-N-methyl-piperidine; DMSO, dimethyl sulfoxide; PSS, physiological salt solution; PBS, phosphate-buffered saline; Vh, holding voltage; SKF-96365, 1-(β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl)-1H-imidazole hydrochloride.
-
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
- Received August 11, 2007.
- Accepted October 9, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|